Imagine trying to breathe through a plastic bag. You struggle. Your heart starts to race. Your head gets dizzy. And all you did was stroll through a park full of blooming flowers. Asthma is one of the ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The flu season has passed, but here's some important news for parents to arm themselves with before next fall. A new study published in Pediatrics on June 4 said a flu shot is key for children with ...
Allergies affect millions of Americans each year, causing symptoms like sneezing, congestion, itchy eyes, fatigue, and even asthma flare ups. For many patients, over-the-counter medications or nasal ...
Chinese scientists have developed a groundbreaking cell therapy that could provide long-term relief for asthma patients with just a single shot. This new treatment, which has shown promising results ...
Tezspire (tezepelumab-ekko) is a monthly injection used to treat severe asthma. It was approved by the FDA in 2021 for use in addition to other asthma controlling medicines in people 12 and older.
ATLANTA — Children with asthma should get flu shots to protect them, but only 3 in 10 do, U.S. health officials said Thursday. "We were surprised at how low the number was," said Susan Brim of the U.S ...
Those trendy weight loss shots everyone’s talking about? Turns out they might do more than shrink your waistline — they could help you breathe easier too. New research involving 60,000 people just ...
Klein is a contributor for TIME. Klein is a contributor for TIME. Nearly a third of American adults have some kind of allergy. If you’re one of them, you’re probably eager to find a solution. Allergy ...
The U.S. Food and Drug Administration (FDA) has approved Exdensur, a twice-yearly severe asthma treatment developed by pharmaceutical company GSK.
GREENWICH, Conn.--(BUSINESS WIRE)--An analysis from Cedar Gate Technologies (Cedar Gate) reveals that only 34.7% of commercially insured patients diagnosed with chronic obstructive pulmonary disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results